first-in-class ketohexokinase (KHK) inhibitor

oral candidate in Ph. II for NAFLD/NASH

from frag.-based screening, SBDD, and opt.

J. Med. Chem., Sep. 27, 2020

Pfizer, Cambridge, MA / Groton, CT

PF-06835919 is an oral first-in-class clinical candidate for NAFLD/NASH targeting ketohexokinase (KHK), an enzyme which initiates the metabolism of fructose. The authors describe a very elegant structure-based design campaign to…


 become a member to continue reading

Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.

  • Stay up-to-date and save more time with exclusive members-only content
  • On-board new team members with educational content and case studies
  • Generate ideas and discussion with easy-to-read slide decks
  • Generate ideas and discussion with easy-to-read slide decks